MarketMoodz
Celcuity Stock Rallies on VIKTORIA-1 Readout; FDA NDA Gets Priority Review
Celcuity shares push higher in premarket trading after positive VIKTORIA-1 Phase 3 results. The company also disclosed that the FDA has accepted its gedatolisib NDA with Priority Review, targeting July 17, 2026.
Key Takeaways
- VIKTORIA-1 met its primary endpoint, delivering progression-free survival gains in HR+/HER2-/PIK3CA wild-type advanced breast cancer after CDK4/6 inhibitor and AI therapy.
- Gedatolisib plus fulvestrant showed PFS improvement versus alpelisib plus fulvestrant on a defined secondary endpoint.
- Celcuity plans to submit the VIKTORIA-1 data to the FDA as part of an sNDA with a target date of July 17, 2026.
- FDA previously accepted Celcuity's NDA for gedatolisib and granted Priority Review (announced January).
People Involved
- No specific individuals mentioned
Entities Involved
- Celcuity, Inc. (CELC)Biotech focusing on targeted therapies for solid tumors
- GedatolisibInvestigational PI3K/mTOR pathway inhibitor
- Alpelisib (BYL-719)PI3K inhibitor used as comparator in VIKTORIA-1 trial
- U.S. Food and Drug Administration (FDA)Regulatory agency overseeing the NDA and Priority Review
MarketMoodz Analysis
A positive Phase 3 readout expands the potential addressable market for gedatolisib in post-CDK4/6 inhibitor settings, potentially catalyzing a re-rating for a biotech microcap that can be highly sensitive to trial data and regulatory milestones.
From a historical lens, small-cap cancer drug developers often see outsized moves on trial results and regulatory updates, but actual approvals and commercial traction lag behind initial optimism. Investors should watch for the full data release, endpoint definitions, and whether the sNDA submission includes additional analyses or companion diagnostics.
Near-term catalysts include the NDA data package, the execution of the sNDA submission path, and any potential partnerships or licensing deals if the data support broader use.
Source: Original Article